Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

MC #22-19

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

NCT #
NCT05252390
Condition(s)
Colorectal, Ovarian, Pancreatic, Solid Tumors, triple negative Breast
Molecular Target(s)
BET
Drug Classification(s)
Small Molecule
Agents(s)
None
Phase(s)
I/II

Mechanism of Action

NUV-868 is a small molecule bromodomain 2 (BD2)-selective bromodomain and extra-terminal domain (BET) inhibitor. The BET family of proteins have critical biological functions and are found to be altered in many human cancers.

Purpose

  •  How much of the study drug can be given alone and in combination with Olaparib or Enzalutamide with an acceptable level of side effects
  •  The effects of the study drug alone and in combination with Olaparib or Enzalutamide (good and bad)
  •  How much of the study drug is absorbed into the blood and how fast it is removed
  •  If research tests can be used in the future to predict who will benefit from the study drug when given alone or in combination with Olaparib or Enzalutamide

Location

MCD

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.